Exhibit 99.1
Bausch + Lomb Announces Fourth-Quarter and Full-Year 2023 Results and
Provides 2024 Guidance
•Fourth-Quarter 2023 Financial Results
◦Revenue of $1.173 Billion
◦GAAP Net Loss Attributable to Bausch + Lomb Corporation of $54 Million
◦Adjusted EBITDA (non-GAAP)1 of $231 Million
◦Revenue Grew 18% as Reported and 19% on a Constant Currency1 Basis Compared to the Fourth Quarter of 2022, Driven by Growth Across All Segments
•Full-Year 2023 Financial Results
◦Revenue of $4.146 Billion
◦GAAP Net Loss Attributable to Bausch + Lomb Corporation of $260 Million
◦Adjusted EBITDA (non-GAAP)1 of $738 Million
◦Revenue Grew 10% as Reported and 12% on a Constant Currency1 Basis Compared to the Full Year of 2022, Driven by Growth Across All Segments
◦Foreign Exchange Negatively Impacted Revenue and Adjusted EBITDA (non-GAAP)1 by Approximately $68 Million and $51 Million, Respectively
VAUGHAN, Ontario, Feb. 21, 2024 – Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its fourth-quarter and full year 2023 financial results.
“Revenue growth in 2023, and in the fourth quarter in particular, exceeded our expectations and set the tone for 2024,” said Brent Saunders, chairman and CEO, Bausch + Lomb. “Double-digit growth is always impressive, but even more so when you consider how we got there. Our quality of growth is what helps set us apart from others.”
Select Fourth-Quarter Company Highlights
•Launched enVista® Aspire monofocal and toric intraocular lenses with Intermediate Optimized optics in the United States
•Launched SeeNa™, an ophthalmic diagnostic system for refractive cataract patients that is fully integrated with Bausch + Lomb’s Eyetelligence™ surgical planning software to help streamline surgical planning and information flow
•Received U.S. Food and Drug Administration approval for TENEO™ Excimer Laser Platform for laser-assisted in situ keratomileusis (LASIK) vision correction surgery for myopia and myopic astigmatism (nearsightedness and nearsightedness with astigmatism)2 – the first excimer platform approved in nearly two decades
___________________________________
1 This is a non-GAAP measure or a non-GAAP ratio. For further information on non-GAAP measures and non-GAAP ratios, please refer to the “Non-GAAP Information” section of this news release. Please also refer to tables at the end of this news release for a reconciliation of this and other non-GAAP measures to the most directly comparable GAAP measure.
2 Nearsightedness (myopia) between -1 and -10 diopters (D) with astigmatism between 0 and -3 D.
Fourth-Quarter and Full-Year 2023 Revenue Performance
Total reported revenue was $1.173 billion for the fourth quarter of 2023, as compared to $996 million in the fourth quarter of 2022, an increase of $177 million, or 18%. Excluding the unfavorable impact of foreign exchange of $9 million, revenue increased by approximately 19% on a constant currency1 basis compared to the fourth quarter of 2022.
Total reported revenue was $4.146 billion for the full year of 2023, as compared to $3.768 billion in the full year of 2022, an increase of $378 million, or 10%. Excluding the unfavorable impact of foreign exchange of $68 million, revenue increased by approximately 12% on a constant currency1 basis compared to the full year of 2022.
Revenue by segment was as follows:
Fourth-Quarter 2023
| (in millions) | Three Months Ended December 31 | Change at Constant Currency1 (non-GAAP) | ||||||||||||||||||||||||||||||
| 2023 | 2022 | Reported Change | Reported Change | |||||||||||||||||||||||||||||
Total Bausch + Lomb Revenue | $1,173 | $996 | $177 | 18 | % | 19 | % | |||||||||||||||||||||||||
Vision Care3 | $662 | $624 | $38 | 6 | % | 8 | % | |||||||||||||||||||||||||
Surgical | $204 | $188 | $16 | 9 | % | 7 | % | |||||||||||||||||||||||||
Pharmaceuticals3 | $307 | $184 | $123 | 67 | % | 66 | % | |||||||||||||||||||||||||
Full-Year 2023
| (in millions) | Twelve Months Ended December 31 | Change at Constant Currency1 (non-GAAP) | ||||||||||||||||||||||||||||||
| 2023 | 2022 | Reported Change | Reported Change | |||||||||||||||||||||||||||||
Total Bausch + Lomb Revenue | $4,146 | $3,768 | $378 | 10 | % | 12 | % | |||||||||||||||||||||||||
Vision Care3 | $2,543 | $2,369 | $174 | 7 | % | 10 | % | |||||||||||||||||||||||||
Surgical | $767 | $718 | $49 | 7 | % | 7 | % | |||||||||||||||||||||||||
Pharmaceuticals3 | $836 | $681 | $155 | 23 | % | 24 | % | |||||||||||||||||||||||||
___________________________________
3 Effective in the first quarter of 2023, certain products historically included in the reported results of the Pharmaceuticals segment are now included in the reported results of the Vision Care segment and certain products included in the reported results of the Vision Care segment are now included in the reported results of the Pharmaceuticals segment. Management believes these movements are necessary in order to better align these products with the groupings of similar products. The net impact of these product movements was not material to the periods presented. Prior period presentations of segment revenues have been conformed to the current segment reporting structure.
Vision Care Segment3
Vision Care segment revenue was $662 million for the fourth quarter of 2023, as compared to $624 million for the fourth quarter of 2022, an increase of $38 million, or 6%. Excluding the unfavorable impact of foreign exchange of $13 million, segment revenue increased on a constant currency1 basis by approximately 8% compared to the fourth quarter of 2022, primarily due to higher sales of Lumify®, Eye Vitamins and Dry Eye Portfolio in our consumer eye care business and higher sales of SiHy Daily lenses and Ultra® within our contact lens business, partially offset by unfilled orders as a result of the implementation of a system upgrade at our Lynchburg distribution facility that impacted our contact lens business.
Vision Care segment revenue was $2.543 billion for the full year of 2023, as compared to $2.369 billion for the full year of 2022, an increase of $174 million, or 7%. Excluding the unfavorable impact of foreign exchange of $61 million, segment revenue increased on a constant currency1 basis by approximately 10% compared to the full year of 2022, primarily due to higher sales of Lumify, Eye Vitamins, Dry Eye Portfolio and Biotrue® in our consumer eye care business and higher sales of SiHy Daily lenses and Ultra within our contact lens business, partially offset by unfilled orders as a result of the implementation of a system upgrade at our Lynchburg distribution facility that impacted our contact lens business.
Surgical Segment
Surgical segment revenue was $204 million for the fourth quarter of 2023, as compared to $188 million for the fourth quarter of 2022, an increase of $16 million, or 9%. Excluding the favorable impact of foreign exchange of $3 million, segment revenue increased on a constant currency1 basis by approximately 7% compared to the fourth quarter of 2022, primarily due to higher sales of consumables, equipment and premium intraocular lenses (“IOLs”).
Surgical segment revenue was $767 million for the full year of 2023, as compared to $718 million for the full year of 2022, an increase of $49 million, or 7%. Excluding the unfavorable impact of foreign exchange of $1 million, segment revenue increased on a constant currency1 basis by approximately 7% compared to the full year of 2022, primarily due to higher sales of consumables, equipment and premium IOLs.
Pharmaceuticals Segment3
Pharmaceuticals segment revenue was $307 million for the fourth quarter of 2023, as compared to $184 million for the fourth quarter of 2022, an increase of $123 million, or 67%. Excluding the favorable impact of foreign exchange of $1 million, segment revenue increased on a constant currency1 basis by approximately 66% compared to the fourth quarter of 2022, primarily due to the acquisition of XIIDRA®, sales of MIEBO® and higher sales of Vyzulta®.
Pharmaceuticals segment revenue was $836 million for the full year of 2023, as compared to $681 million for the full year of 2022, an increase of $155 million, or 23%. Excluding the unfavorable impact of foreign exchange of $6 million, segment revenue increased on a constant currency1 basis by approximately 24% compared to the full year of 2022, primarily due to the acquisition of XIIDRA, launch of MIEBO and higher sales of Vyzulta, U.S. generics business and International Pharmaceuticals.
Operating Results
Operating income was $49 million for the fourth quarter of 2023, as compared to $51 million for the fourth quarter of 2022, a decrease of $2 million. Operating income was $130 million for the full year of 2023, as compared to $207 million for the full year of 2022, a decrease of $77 million.
For both the fourth quarter and full year of 2023, the changes in operating income were largely driven by an increase in selling, general and administrative expenses driven by product launches. Full year 2023 was also impacted by Business Transformation Costs and dis-synergy costs associated with the company becoming a stand-alone entity. The company is committed to continuing to maintain a disciplined approach to cost management and to leverage its infrastructure.
Net Loss
Net loss attributable to Bausch + Lomb Corporation for the fourth quarter of 2023 was $54 million, as compared to $1 million for the fourth quarter of 2022, an unfavorable change of $53 million. Net loss attributable to Bausch + Lomb Corporation for the full year of 2023 was $260 million, as compared to a net income attributable to Bausch + Lomb Corporation of $6 million for the full year of 2022, an unfavorable change of $266 million.
For the fourth quarter of 2023, the change was primarily due to higher interest expense and the decrease in operating results noted above.
For the full year of 2023, the change was primarily due to higher interest expense, the decrease in operating results noted above and foreign exchange headwinds.
Adjusted net income attributable to Bausch + Lomb Corporation (non-GAAP)1 for the fourth quarter of 2023 was $83 million, as compared to $80 million for the fourth quarter of 2022, an increase of $3 million.
Adjusted net income (non-GAAP)1 for the full year of 2023 was $258 million, as compared to $375 million for the full year of 2022, a decrease of $117 million.
Cash from Operations
Cash flow from operations for the fourth quarter of 2023 was $15 million, as compared to $159 million for the fourth quarter of 2022, a decrease of $144 million. Cash flow from operations was negatively impacted in the fourth quarter of 2023 primarily by the timing of collections and payments in the ordinary course of business and a strategic increase in inventories.
Cash flow used in operations for the full year of 2023 was $17 million, as compared to cash flow from operations of $345 million for the full year of 2022, a decrease of $362 million. Cash flow was negatively impacted in the full year of 2023 primarily by a strategic increase in inventories, decrease in operating results, and the timing of collections and payments in the ordinary course of business.
Earnings Per Share
GAAP Earnings Per Share (“EPS”) Basic and Diluted attributable to Bausch + Lomb Corporation for the fourth quarter of 2023 was ($0.15), as compared to $0.00 for the fourth quarter of 2022. Adjusted EPS attributable to Bausch + Lomb Corporation (non-GAAP)1 for the fourth quarter of 2023 was $0.24, as compared to $0.23 for the fourth quarter of 2022.
GAAP EPS Basic and Diluted attributable to Bausch + Lomb Corporation for the full year of 2023 was ($0.74), as compared to $0.02 for the full year of 2022. Adjusted EPS attributable to Bausch + Lomb Corporation (non-GAAP)1 for the full year of 2023 was $0.73, as compared to $1.07 for the full year of 2022.
Adjusted EBITDA (non-GAAP)1
Adjusted EBITDA (non-GAAP)1 was $231 million for the fourth quarter of 2023, as compared to $181 million for the fourth quarter of 2022, an increase of $50 million, primarily due to the acquisition of XIIDRA and revenue growth across all segments.
Adjusted EBITDA (non-GAAP)1 was $738 million for the full year of 2023, as compared to $720 million for the full year of 2022, an increase of $18 million, primarily due to the acquisition of XIIDRA and revenue growth across all segments, partially offset by foreign exchange headwinds.
2024 Financial Outlook4
Bausch + Lomb provided guidance for the full year of 2024, as follows.
| As of Feb. 21, 2024 | |||||||||||||||||
| Full-year revenue | • $4.600 - $4.700 billion | ||||||||||||||||
• ~12% - 14% constant currency growth1 | |||||||||||||||||
Full-year Adjusted EBITDA (non-GAAP)1 | • $840 - $890 million | ||||||||||||||||
| Foreign exchange headwinds for the full year | • Revenue: -$40 million | ||||||||||||||||
Other than with respect to GAAP revenue, the company only provides guidance on a non-GAAP basis. The company does not provide a reconciliation of forward-looking Adjusted EBITDA (non-GAAP)1 to GAAP net income (loss) attributable to Bausch + Lomb Corporation or of forward-looking constant currency revenue growth1 to reported revenue growth, due to the inherent difficulty in forecasting and quantifying certain amounts that are necessary for such reconciliations. These amounts may be material and, therefore, could result in the projected GAAP measure or ratio being materially different or less than the projected non-GAAP measure or ratio. These statements represent forward-looking information and may represent a financial outlook, and actual results may vary. Please see the risks and assumptions referred to in the Forward-looking Statements section of this news release.
Balance Sheet Highlights
•Bausch + Lomb’s cash, cash equivalents and restricted cash were $334 million at Dec. 31, 2023
•Basic weighted average shares outstanding for the fourth quarter of 2023 were 350.8 million, and diluted weighted average shares outstanding for the fourth quarter of 2023 were 352.2 million5
•Basic weighted average shares outstanding for the full year of 2023 were 350.5 million, and diluted weighted average shares outstanding for the full year of 2023 were 352 million5
___________________________________
4 The guidance in this news release is only effective as of the date given, Feb. 21, 2024, and will not be updated or affirmed unless and until the company publicly announces updated or affirmed guidance. Distribution or reference of this news release following Feb. 21, 2024, does not constitute the company reaffirming guidance. See the “Forward-looking Statements” section for further information.
5 Diluted weighted average shares includes the dilutive impact of options, performance based restricted stock units and restricted stock units, which are approximately 1,400,000 common shares for the 3 months ended December 31, 2023 and approximately 1,500,000 common shares for the 12 months ended December 31, 2023, and which are excluded when calculating GAAP diluted loss per share because the effect of including the impact would be anti-dilutive.
Conference Call Details
| Date: | Wednesday, Feb. 21, 2024 | ||||
| Time: | 8:00 a.m. ET | ||||
| Webcast: | https://www.webcaster4.com/Webcast/Page/2883/49630 | ||||
| Participant Event Dial-in: | +1 (888) 506-0062 (North America) +1 (973) 528-0011 (International) | ||||
| Participant Access Code: | 181271 | ||||
| Replay Dial-in: | +1 (877) 481-4010 (North America) +1 (919) 882-2331 (International) | ||||
| Replay Passcode: | 49630 (replay available until Mar. 6, 2024) | ||||
About Bausch + Lomb
Bausch + Lomb is dedicated to protecting and enhancing the gift of sight for millions of people around the world – from birth through every phase of life. Its comprehensive portfolio of approximately 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments. Founded in 1853, Bausch + Lomb has a significant global research and development, manufacturing and commercial footprint with approximately 13,000 employees and a presence in nearly 100 countries. Bausch + Lomb is headquartered in Vaughan, Ontario with corporate offices in Bridgewater, New Jersey. For more information, visit www.bausch.com and connect with us on X, LinkedIn, Facebook and Instagram.
Forward-looking Statements
This news release contains forward-looking information and statements within the meaning of applicable securities laws (collectively, “forward-looking statements”), which may generally be identified by the use of the words “anticipates,” “hopes,” “expects,” “intends,” “plans,” “projects,” “predicts,” “forecasts,” “should,” “could,” “would,” “may,” “might,” “will,” “strive,” “believes,” “estimates,” “potential,” “target,” “guidance,” “outlook,” or “continue” and positive and negative variations or similar expressions and phrases or statements that certain actions, events or results may, could, should or will be achieved, received or taken, or will occur or result, and similar such expressions also identify forward-looking information. Forward-looking statements include statements regarding Bausch + Lomb’s future prospects and performance, including the company’s 2024 full-year guidance, and the company’s planned approach to cost management. These forward-looking statements, including the company’s full-year guidance, are based upon the current expectations and beliefs of management and are provided for the purpose of providing additional information about such expectations and beliefs, and readers are cautioned that these statements may not be appropriate for other purposes. These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties discussed in Bausch + Lomb’s filings with the U.S. Securities and Exchange Commission (“SEC”) and the Canadian Securities Administrators (the “CSA”) (including the company’s Annual Report on Form 10-K for the year ended Dec. 31, 2023 (which is anticipated to be filed with the SEC and CSA on Feb. 21, 2024) and its most recent quarterly filings), which factors are incorporated herein by reference. They also include, but are not limited to, risks and uncertainties relating to the expected timing of resolving the disruptions (including unfulfilled orders) caused by the implementation of a system upgrade at our Lynchburg distribution facility. They also include risks and uncertainties respecting the proposed plan to spin off or separate Bausch + Lomb from Bausch Health Companies Inc. (“BHC”), including the expected benefits
and costs of the spinoff transaction, the expected timing of completion of the spinoff transaction and its terms (including the expectation that the spinoff transaction will be completed following the achievement of targeted net leverage ratios, subject to receipt of applicable shareholder and other necessary approvals), the ability to complete the spinoff transaction considering the various conditions to the completion of the spinoff transaction (some of which are outside the company’s and BHC’s control, including conditions related to regulatory matters and receipt of applicable shareholder and other approvals), the impact of any potential sales of the company’s common shares by BHC, that market or other conditions are no longer favorable to completing the transaction, that applicable shareholder, stock exchange, regulatory or other approval is not obtained on the terms or timelines anticipated or at all, business disruption during the pendency of or following the spinoff transaction, diversion of management time on spinoff transaction-related issues, retention of existing management team members, the reaction of customers and other parties to the spinoff transaction, the structure of the spinoff transaction and related distribution, the qualification of the spinoff transaction as a tax-free transaction for Canadian and/or U.S. federal income tax purposes (including whether or not an advance ruling from the Canada Revenue Agency and/or the Internal Revenue Service will be sought or obtained), the ability of the company and BHC to satisfy the conditions required to maintain the tax-free status of the spinoff transaction (some of which are beyond their control), other potential tax or other liabilities that may arise as a result of the spinoff transaction, the potential dis-synergy costs resulting from the spinoff transaction, the impact of the spinoff transaction on relationships with customers, suppliers, employees and other business counterparties, general economic conditions, conditions in the markets the company is engaged in, behavior of customers, suppliers and competitors, technological developments and legal and regulatory rules affecting the company’s business. In particular, the company can offer no assurance that any spinoff transaction will occur at all, or that any spinoff transaction will occur on the terms and timelines anticipated by the company and BHC. They also include risks and uncertainties respecting the acquisition of XIIDRA® and certain other ophthalmology assets, including the company’s ability to effectively and efficiently integrate the acquired business into its existing business; the effect of the transaction on Bausch + Lomb’s ability to maintain relationships with customers, suppliers and other business partners; risks relating to potential diversion of management attention away from Bausch + Lomb’s ongoing business operations; risks relating to increased levels of debt as a result of debt incurred to finance such transaction, including in regards to compliance with our debt covenants; and risks that the company may not realize the expected benefits of that transaction on a timely basis or at all. Finally, they also include, but are not limited to, risks and uncertainties caused by or relating to adverse economic conditions and other macroeconomic factors, including inflation, slower growth or a potential recession, which could adversely impact our revenue, expenses and resulting margins, and economic factors over which we have no control, including inflationary pressures as a result of historically high domestic and global inflation and otherwise, interest rates, foreign currency rates, and the positional effect of such factors on revenue, expenses and resulting margins. In addition, certain material factors and assumptions have been applied in making these forward-looking statements, including, without limitation, the assumption that the risks and uncertainties outlined above will not cause actual results or events to differ materially from those described in these forward-looking statements. In addition, management has also made certain assumptions regarding our 2024 full-year guidance with respect to expectations regarding base performance growth, expectations regarding performance of certain of our key products (including XIIDRA® and MIEBO®), currency impact, run-rate dis-synergies and inflation, expectations regarding adjusted gross margin (non-GAAP), adjusted SG&A expense (non-GAAP) and the company’s ability to continue to manage such expense in the manner anticipated and the anticipated timing and extent of the company’s R&D expense.
Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Bausch + Lomb undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, unless required by law.
Links provided in this news release are solely for information purposes and do not constitute Bausch + Lomb affirming any forward-looking statements contained in the linked content.
Non-GAAP Information
To supplement the financial measures prepared in accordance with U.S. generally accepted accounting principles (GAAP), the company uses certain non-GAAP financial measures and ratios. Management uses these non-GAAP measures and ratios as key metrics in the evaluation of the company’s performance and the consolidated financial results and, in part, in the determination of cash bonuses for its executive officers. The company believes these non-GAAP measures and ratios are useful to investors in their assessment of our operating performance and the valuation of the company. In addition, these non-GAAP measures and ratios address questions the company routinely receives from analysts and investors, and in order to assure that all investors have access to similar data, the company has determined that it is appropriate to make this data available to all investors.
These measures and ratios do not have any standardized meaning under GAAP and other companies may use similarly titled non-GAAP financial measures and ratios that are calculated differently from the way we calculate such measures and ratios. Accordingly, our non-GAAP financial measures and ratios may not be comparable to similar non-GAAP measures and ratios of other companies. We caution investors not to place undue reliance on such non-GAAP measures and ratios, but instead to consider them with the most directly comparable GAAP measures and ratios. Non-GAAP financial measures and ratios have limitations as analytical tools and should not be considered in isolation. They should be considered as a supplement to, not a substitute for, or superior to, the corresponding measures calculated in accordance with GAAP.
The reconciliations of these historic non-GAAP financial measures and ratios to the most directly comparable financial measures and ratios calculated and presented in accordance with GAAP are shown in the tables below.
Specific Non-GAAP Measures
EBITDA and Adjusted EBITDA
EBITDA (non-GAAP) is Net income (loss) attributable to Bausch + Lomb Corporation (its most directly comparable U.S. GAAP financial measure) adjusted for interest, income taxes, depreciation and amortization. Adjusted EBITDA (non-GAAP) is EBITDA (non-GAAP) further adjusted for the items described below. Management believes that Adjusted EBITDA (non-GAAP), along with the GAAP measures used by management, most appropriately reflect how the company measures the business internally and sets operational goals and incentives. In particular, the company believes that Adjusted EBITDA (non-GAAP) focuses management on the company’s underlying operational results and business performance. As a result, the company uses Adjusted EBITDA (non-GAAP) both to assess the actual financial performance of the company and to forecast future results as part of its guidance. Management believes Adjusted EBITDA (non-GAAP) is a useful measure to evaluate current performance. Adjusted EBITDA (non-GAAP) is intended to show our unleveraged, pre-tax operating results and therefore reflects our financial performance based on operational factors. In addition, cash bonuses for the company’s executive officers and other key employees are based, in part, on the achievement of certain Adjusted EBITDA (non-GAAP) targets.
Adjusted EBITDA (non-GAAP) is Net income (loss) attributable to Bausch + Lomb Corporation (its most directly comparable U.S. GAAP financial measure) adjusted for interest expense, net, (benefit from) provision for income taxes, depreciation and amortization and further adjusted for the following items:
•Asset impairments: The company has excluded the impact of impairments of finite-lived and indefinite-lived intangible assets as such amounts are inconsistent in amount and frequency and are significantly impacted by the timing and/or size of acquisitions and divestitures. The company believes that the adjustments of these items correlate with the sustainability of the company’s operating performance. Although the company excludes impairments of intangible assets from measuring the performance of the company and its business, the company believes that it is important for investors to understand that intangible assets contribute to revenue generation.
•Restructuring, integration and transformation costs: The company has incurred restructuring costs as it implemented certain strategies, which involved, among other things, improvements to its
infrastructure and operations, internal reorganizations and impacts from the divestiture of assets and businesses. With regard to infrastructure and operational improvements which the company has taken to improve efficiencies in the businesses and facilities, these tend to be costs intended to right size the business or organization that fluctuate significantly between periods in amount, size and timing, depending on the improvement project, reorganization or transaction. Additionally, with the completion of the Bausch + Lomb IPO, as the company prepares for post-separation operations, the company is launching certain transformation initiatives that will result in certain changes to and investment in its organizational structure and operations. These transformation initiatives arise outside of the ordinary course of continuing operations and, as is the case with the company’s restructuring efforts, costs associated with these transformation initiatives are expected to fluctuate between periods in amount, size and timing. These out-of-the-ordinary-course charges include third-party advisory costs, as well as certain compensation-related costs (including costs associated with changes in our executive officers, such as the severance costs associated with the departure of the company’s former CEO and the costs associated with the appointment of the company’s current CEO). Investors should understand that the outcome of these transformation initiatives may result in future restructuring actions and certain of these charges could recur. The company believes that the adjustments of these items provide supplemental information with regard to the sustainability of the company’s operating performance, allow for a comparison of the financial results to historical operations and forward-looking guidance and, as a result, provide useful supplemental information to investors.
•Acquisition-related costs and adjustments excluding amortization of intangible assets: The company has excluded the impact of acquisition-related costs and fair value inventory step-up resulting from acquisitions as the amounts and frequency of such costs and adjustments are not consistent and are significantly impacted by the timing and size of its acquisitions. In addition, the company excludes the impact of acquisition-related contingent consideration non-cash adjustments due to the inherent uncertainty and volatility associated with such amounts based on changes in assumptions with respect to fair value estimates, and the amount and frequency of such adjustments are not consistent and are significantly impacted by the timing and size of the company’s acquisitions, as well as the nature of the agreed-upon consideration.
•Share-based compensation: The company excludes costs relating to share-based compensation. The company believes that the exclusion of share-based compensation expense assists investors in the comparisons of operating results to peer companies. Share-based compensation expense can vary significantly based on the timing, size and nature of awards granted.
•Separation costs and separation-related costs: The company has excluded certain costs incurred in connection with activities taken to: (i) separate the Bausch + Lomb business from the remainder of BHC and (ii) register the Bausch + Lomb business as an independent publicly traded entity. Separation costs are incremental costs directly related to effectuating the separation of the Bausch + Lomb business from the remainder of BHC and include, but are not limited to, legal, audit and advisory fees, talent acquisition costs and costs associated with establishing a new Board of Directors and Audit Committee. Separation-related costs are incremental costs indirectly related to the separation of the Bausch + Lomb business from the remainder of BHC and include, but are not limited to, IT infrastructure and software licensing costs, rebranding costs and costs associated with facility relocation and/or modification. As these costs arise from events outside of the ordinary course of continuing operations, the company believes that the adjustments of these items provide supplemental information with regard to the sustainability of the company’s operating performance, allow for a comparison of the financial results to historical operations and forward-looking guidance and, as a result, provide useful supplemental information to investors.
•Other Non-GAAP adjustments: The company also excludes certain other amounts, including IT infrastructure investment, litigation and other matters, gain/(loss) on sales of assets and certain other amounts that are the result of other, non-comparable events to measure operating performance if and when present in the periods presented. These events arise outside of the ordinary course of continuing operations. Given the unique nature of the matters relating to these costs, the company believes these items are not routine operating expenses. For example, legal settlements and judgments vary significantly, in their nature, size and frequency, and, due to this volatility, the company believes the costs associated with legal settlements and judgments are not
routine operating expenses. The company has also excluded certain other costs, including settlement costs associated with the conversion of a portion of the company’s defined benefit plan in Ireland to a defined contribution plan. The company excluded these costs as this event is outside of the ordinary course of continuing operations and is infrequent in nature. The company believes that the exclusion of such out-of-the-ordinary-course amounts provides supplemental information to assist in the comparison of the financial results of the company from period to period and, therefore, provides useful supplemental information to investors. However, investors should understand that many of these costs could recur and that companies in our industry often face litigation.
Adjusted Net Income (non-GAAP)
Adjusted net income (non-GAAP) is net income (loss) attributable to Bausch + Lomb Corporation (its most directly comparable GAAP financial measure) adjusted for asset impairments, restructuring, integration and transformation costs, acquisition-related contingent consideration, separation costs and separation-related costs and other non-GAAP adjustments, as these adjustments are described above, and further adjusted for amortization of intangible assets and acquisition-related costs and adjustments excluding amortization of intangible assets, as described below:
•Amortization of intangible assets: The company has excluded the impact of amortization of intangible assets, as such amounts are inconsistent in amount and frequency and are significantly impacted by the timing and/or size of acquisitions. The company believes that the adjustments of these items correlate with the sustainability of the company’s operating performance. Although the company excludes the amortization of intangible assets from its non-GAAP expenses, the company believes that it is important for investors to understand that such intangible assets contribute to revenue generation. Amortization of intangible assets that relate to past acquisitions will recur in future periods until such intangible assets have been fully amortized. Any future acquisitions may result in the amortization of additional intangible assets.
•Acquisition-related costs and adjustments excluding amortization of intangible assets: In addition to the acquisition-related costs and adjustments as described above, the company has excluded the expense directly attributable to one-time commitment and structuring fees related to a bridge loan facility put in place prior to the acquisition of XIIDRA and certain other ophthalmology assets. The company excluded these costs as they are outside of the ordinary course of continuing operations and are infrequent in nature. The company believes that the exclusion of such out-of-the-ordinary-course amounts provides supplemental information to assist in the comparison of the financial results of the company from period to period and, therefore, provides useful supplemental information to investors.
Adjusted net income (non-GAAP) excludes the impact of these certain items that may obscure trends in the company’s underlying performance. Management uses Adjusted net income (non-GAAP) for strategic decision making, forecasting future results and evaluating current performance. By disclosing this non-GAAP measure, it is management’s intention to provide investors with a meaningful, supplemental comparison of the company’s operating results and trends for the periods presented. Management believes that this measure is also useful to investors as such measure allows investors to evaluate the company’s performance using the same tools that management uses to evaluate past performance and prospects for future performance. Accordingly, the company believes that Adjusted net income (non-GAAP) is useful to investors in their assessment of the company’s operating performance and the valuation of the company. It is also noted that, in recent periods, our GAAP net income (loss) attributable to Bausch + Lomb Corporation was significantly lower than our Adjusted net income (non-GAAP).
Constant Currency
Constant currency change or constant currency revenue growth is a change in GAAP revenue (its most directly comparable GAAP financial measure) on a period-over-period basis adjusted for changes in foreign currency exchange rates. The company uses Constant Currency revenue (non-GAAP) and Constant Currency revenue Growth (non-GAAP) to assess performance of its reportable segments, and
the company in total, without the impact of foreign currency exchange fluctuations. The company believes that such measures are useful to investors as they provide a supplemental period-to-period comparison. Although changes in foreign currency exchange rates are part of our business, they are not within management’s control. Changes in foreign currency exchange rates, however, can mask positive or negative trends in the underlying business performance. Constant currency impact is determined by comparing 2023 reported amounts adjusted to exclude currency impact, calculated using 2022 monthly average exchange rates, to the actual 2022 reported amounts.
Adjusted EPS (non-GAAP)
Adjusted earnings per share or Adjusted EPS (non-GAAP) is calculated as Diluted income per share attributable to Bausch + Lomb Corporation (“GAAP EPS”) (its most directly comparable GAAP financial measure), adjusted for the per diluted share impact of each adjustment made to reconcile Net income (loss) attributable to Bausch + Lomb Corporation to Adjusted net income (non-GAAP) as discussed above. Like Adjusted net income (non-GAAP), Adjusted EPS (non-GAAP) excludes the impact of certain items that may obscure trends in the company’s underlying performance on a per share basis. By disclosing this non-GAAP measure, it is management’s intention to provide investors with a meaningful, supplemental comparison of the company’s results and trends for the periods presented on a diluted share basis. Accordingly, the company believes that Adjusted EPS (non-GAAP) is useful to investors in their assessment of the company’s operating performance, the valuation of the company and an investor’s return on investment. It is also noted that, for the periods presented, our GAAP EPS was significantly lower than our Adjusted EPS (non-GAAP).
© 2024 Bausch + Lomb.
| Media Contact: | |||||
| T.J. Crawford | |||||
| tj.crawford@bausch.com | |||||
| (908) 705-2851 | |||||
| Investor Contact: | |||||
| George Gadkowski | |||||
| george.gadkowski@bausch.com | |||||
| (877) 354-3705 (toll free) | |||||
| (908) 927-0735 | |||||
FINANCIAL TABLES FOLLOW
| Bausch + Lomb Corporation | Table 1 | |||||||||||||||||||||||||
| Consolidated Statements of Operations | ||||||||||||||||||||||||||
| For the Three and Twelve Months Ended December 31, 2023 and 2022 | ||||||||||||||||||||||||||
| (unaudited) | ||||||||||||||||||||||||||
| Three Months Ended | Twelve Months Ended | |||||||||||||||||||||||||
| December 31, | December 31, | |||||||||||||||||||||||||
(in millions, except per share amounts) | 2023 | 2022 | 2023 | 2022 | ||||||||||||||||||||||
| Revenues | ||||||||||||||||||||||||||
| Product sales | $ | 1,168 | $ | 991 | $ | 4,131 | $ | 3,746 | ||||||||||||||||||
| Other revenues | 5 | 5 | 15 | 22 | ||||||||||||||||||||||
| 1,173 | 996 | 4,146 | 3,768 | |||||||||||||||||||||||
| Expenses | ||||||||||||||||||||||||||
| Cost of goods sold (excluding amortization and impairments of intangible assets) | 461 | 418 | 1,640 | 1,511 | ||||||||||||||||||||||
| Cost of other revenues | — | 2 | 2 | 8 | ||||||||||||||||||||||
| Selling, general and administrative | 483 | 386 | 1,736 | 1,478 | ||||||||||||||||||||||
| Research and development | 80 | 78 | 324 | 307 | ||||||||||||||||||||||
| Amortization of intangible assets | 80 | 56 | 240 | 244 | ||||||||||||||||||||||
| Other expense, net | 20 | 5 | 74 | 13 | ||||||||||||||||||||||
| 1,124 | 945 | 4,016 | 3,561 | |||||||||||||||||||||||
| Operating income | 49 | 51 | 130 | 207 | ||||||||||||||||||||||
| Interest income | 3 | 3 | 15 | 6 | ||||||||||||||||||||||
| Interest expense | (99) | (47) | (283) | (146) | ||||||||||||||||||||||
| Foreign exchange and other | (10) | (9) | (28) | 6 | ||||||||||||||||||||||
| (Loss) income before provision for income taxes | (57) | (2) | (166) | 73 | ||||||||||||||||||||||
| Benefit (provision) for income taxes | 6 | 2 | (82) | (58) | ||||||||||||||||||||||
| Net (loss) income | (51) | — | (248) | 15 | ||||||||||||||||||||||
| Net income attributable to noncontrolling interest | (3) | (1) | (12) | (9) | ||||||||||||||||||||||
| Net (loss) income attributable to Bausch + Lomb Corporation | $ | (54) | $ | (1) | $ | (260) | $ | 6 | ||||||||||||||||||
| Basic and diluted (loss) income per share attributable to Bausch + Lomb Corporation | $ | (0.15) | $ | — | $ | (0.74) | $ | 0.02 | ||||||||||||||||||
| Basic weighted-average common shares | 350.8 | 350.0 | 350.5 | 350.0 | ||||||||||||||||||||||
| Diluted weighted-average common shares | 350.8 | 350.0 | 350.5 | 350.2 | ||||||||||||||||||||||
| Bausch + Lomb Corporation | Table 2 | |||||||||||||||||||||||||
| Reconciliation of GAAP Net (Loss) Income and Diluted (Loss) Income per Share Attributable to Bausch + Lomb Corporation to Adjusted Net Income (non-GAAP) and Adjusted Earnings Per Share (non-GAAP) | ||||||||||||||||||||||||||
| For the Three and Twelve Months Ended December 31, 2023 and 2022 | ||||||||||||||||||||||||||
| (unaudited) | ||||||||||||||||||||||||||
| Three Months Ended December 31, | ||||||||||||||||||||||||||
| 2023 | 2022 | |||||||||||||||||||||||||
(in millions, except per share amounts) | Income (Expense) | Earnings per Share Impact (b) | Income (Expense) | Earnings per Share Impact (b) | ||||||||||||||||||||||
| Net loss and Diluted loss per share attributable to Bausch + Lomb Corporation | $ | (54) | $ | (0.15) | $ | (1) | $ | — | ||||||||||||||||||
Non-GAAP adjustments: (a) | ||||||||||||||||||||||||||
| Amortization of intangible assets | 80 | 0.23 | 56 | 0.16 | ||||||||||||||||||||||
| Restructuring, integration and transformation costs | 27 | 0.08 | 21 | 0.06 | ||||||||||||||||||||||
| Acquisition-related costs and adjustments (excluding amortization of intangible assets) | 29 | 0.08 | 1 | — | ||||||||||||||||||||||
| Separation costs and separation-related costs | 3 | 0.01 | 7 | 0.02 | ||||||||||||||||||||||
| Other | 4 | 0.01 | 1 | — | ||||||||||||||||||||||
| Tax effect of non-GAAP adjustments | (6) | (0.02) | (5) | (0.01) | ||||||||||||||||||||||
| Total non-GAAP adjustments | 137 | 0.39 | 81 | 0.23 | ||||||||||||||||||||||
| Adjusted net income (non-GAAP) and Adjusted earnings per share (non-GAAP) | $ | 83 | $ | 0.24 | $ | 80 | $ | 0.23 | ||||||||||||||||||
| Twelve Months Ended December 31, | ||||||||||||||||||||||||||
| 2023 | 2022 | |||||||||||||||||||||||||
(in millions, except per share amounts) | Income (Expense) | Earnings per Share Impact (b) | Income (Expense) | Earnings per Share Impact (b) | ||||||||||||||||||||||
| Net (loss) income and Diluted (loss) income per share attributable to Bausch + Lomb Corporation | $ | (260) | $ | (0.74) | $ | 6 | $ | 0.02 | ||||||||||||||||||
Non-GAAP adjustments: (a) | ||||||||||||||||||||||||||
| Amortization of intangible assets | 240 | 0.68 | 244 | 0.70 | ||||||||||||||||||||||
| Asset impairments | — | — | 1 | — | ||||||||||||||||||||||
| Restructuring, integration and transformation costs | 123 | 0.35 | 36 | 0.10 | ||||||||||||||||||||||
| Acquisition-related costs and adjustments (excluding amortization of intangible assets) | 66 | 0.19 | (4) | (0.01) | ||||||||||||||||||||||
| Separation costs and separation-related costs | 10 | 0.03 | 35 | 0.10 | ||||||||||||||||||||||
| Other | 9 | 0.03 | 7 | 0.02 | ||||||||||||||||||||||
| Tax effect of non-GAAP adjustments | 70 | 0.19 | 50 | 0.14 | ||||||||||||||||||||||
| Total non-GAAP adjustments | 518 | 1.47 | 369 | 1.05 | ||||||||||||||||||||||
| Adjusted net income (non-GAAP) and Adjusted earnings per share (non-GAAP) | $ | 258 | $ | 0.73 | $ | 375 | $ | 1.07 | ||||||||||||||||||
(a) The components of and further details respecting each of these non-GAAP adjustments and the financial statement line item to which each component relates can be found on Table 2a.
(b) On April 28, 2022, Bausch + Lomb effected a share consolidation as a result of which it had 350,000,000 issued and outstanding common shares. These common shares are treated as issued and outstanding at January 1, 2022 for purposes of calculating Basic and diluted income per share attributable to Bausch + Lomb Corporation.
| Bausch + Lomb Corporation | Table 2a | |||||||||||||||||||||||||
| Reconciliation of GAAP to Non-GAAP Financial Information | ||||||||||||||||||||||||||
| For the Three and Twelve Months Ended December 31, 2023 and 2022 | ||||||||||||||||||||||||||
| (unaudited) | ||||||||||||||||||||||||||
| Three Months Ended | Twelve Months Ended | |||||||||||||||||||||||||
| December 31, | December 31, | |||||||||||||||||||||||||
| (in millions) | 2023 | 2022 | 2023 | 2022 | ||||||||||||||||||||||
| Cost of goods sold reconciliation: | ||||||||||||||||||||||||||
| GAAP Cost of goods sold (excluding amortization and impairments of intangible assets) | $ | 461 | $ | 418 | $ | 1,640 | $ | 1,511 | ||||||||||||||||||
Fair value inventory step-up resulting from acquisitions (a) | (21) | — | (23) | — | ||||||||||||||||||||||
| Adjusted cost of goods sold (excluding amortization and impairments of intangible assets) (non-GAAP) | $ | 440 | $ | 418 | $ | 1,617 | $ | 1,511 | ||||||||||||||||||
| Selling, general and administrative reconciliation: | ||||||||||||||||||||||||||
| GAAP Selling, general and administrative | $ | 483 | $ | 386 | $ | 1,736 | $ | 1,478 | ||||||||||||||||||
Separation-related costs (b) | (2) | (5) | (7) | (26) | ||||||||||||||||||||||
Transformation costs (c) | (16) | (20) | (80) | (31) | ||||||||||||||||||||||
Other (d) | — | — | 1 | — | ||||||||||||||||||||||
| Adjusted selling, general and administrative (non-GAAP) | $ | 465 | $ | 361 | $ | 1,650 | $ | 1,421 | ||||||||||||||||||
| Research and development reconciliation: | ||||||||||||||||||||||||||
| GAAP Research and development | $ | 80 | $ | 78 | $ | 324 | $ | 307 | ||||||||||||||||||
Separation-related costs (b) | (1) | — | (2) | — | ||||||||||||||||||||||
| Adjusted research and development (non-GAAP) | $ | 79 | $ | 78 | $ | 322 | $ | 307 | ||||||||||||||||||
| Amortization of intangible assets reconciliation: | ||||||||||||||||||||||||||
| GAAP Amortization of intangible assets | $ | 80 | $ | 56 | $ | 240 | $ | 244 | ||||||||||||||||||
Amortization of intangible assets (e) | (80) | (56) | (240) | (244) | ||||||||||||||||||||||
| Adjusted amortization of intangible assets (non-GAAP) | $ | — | $ | — | $ | — | $ | — | ||||||||||||||||||
Other expense, net reconciliation: | ||||||||||||||||||||||||||
GAAP Other expense, net | $ | 20 | $ | 5 | $ | 74 | $ | 13 | ||||||||||||||||||
Litigation and other matters (d) | (1) | (1) | (3) | (1) | ||||||||||||||||||||||
Restructuring and integration costs (c) | (11) | (1) | (43) | (5) | ||||||||||||||||||||||
Asset impairments (f) | — | — | — | (1) | ||||||||||||||||||||||
Separation costs (b) | — | (2) | (1) | (9) | ||||||||||||||||||||||
Acquisition-related costs (a) | (6) | (1) | (25) | (1) | ||||||||||||||||||||||
Acquisition-related contingent consideration (a) | (2) | — | (2) | 5 | ||||||||||||||||||||||
| Adjusted other expense, net (non-GAAP) | $ | — | $ | — | $ | — | $ | 1 | ||||||||||||||||||
| Interest expense reconciliation: | ||||||||||||||||||||||||||
| GAAP Interest expense | $ | (99) | $ | (47) | $ | (283) | $ | (146) | ||||||||||||||||||
Acquisition-related financing costs (a) | — | — | 16 | — | ||||||||||||||||||||||
| Adjusted interest expense (non-GAAP) | $ | (99) | $ | (47) | $ | (267) | $ | (146) | ||||||||||||||||||
| Foreign exchange and other reconciliation: | ||||||||||||||||||||||||||
| GAAP Foreign exchange and other | $ | (10) | $ | (9) | $ | (28) | $ | 6 | ||||||||||||||||||
Other (d) | 3 | — | 7 | 6 | ||||||||||||||||||||||
| Adjusted foreign exchange and other (non-GAAP) | $ | (7) | $ | (9) | $ | (21) | $ | 12 | ||||||||||||||||||
| Provision for income taxes reconciliation: | ||||||||||||||||||||||||||
| GAAP benefit (provision) for income taxes | $ | 6 | $ | 2 | $ | (82) | $ | (58) | ||||||||||||||||||
Tax effect of non-GAAP adjustments (g) | (6) | (5) | 70 | 50 | ||||||||||||||||||||||
| Adjusted provision for income taxes (non-GAAP) | $ | — | $ | (3) | $ | (12) | $ | (8) | ||||||||||||||||||
(a) Represents the four components of the non-GAAP adjustment of “Acquisition-related costs and adjustments (excluding amortization of intangible assets)” (see Table 2).
(b) Represents the three components of the non-GAAP adjustment of “Separation costs and separation-related costs” (see Table 2).
(c) Represents the two components of the non-GAAP adjustment of “Restructuring, integration and transformation costs” (see Table 2).
(d) Represents the three components of the non-GAAP adjustment of “Other” (see Table 2).
(e) Represents the sole component of the non-GAAP adjustment of “Amortization of intangible assets” (see Table 2).
(f) Represents the sole component of the non-GAAP adjustment of “Asset impairments” (see Table 2).
(g) Represents the sole component of the non-GAAP adjustment of “Tax effect of non-GAAP adjustments” (see Table 2).
| Bausch + Lomb Corporation | Table 2b | ||||||||||||||||||||||||||||
| Reconciliation of GAAP Net (Loss) Income to Adjusted EBITDA (non-GAAP) | |||||||||||||||||||||||||||||
| For the Three and Twelve Months Ended December 31, 2023 and 2022 | |||||||||||||||||||||||||||||
| (unaudited) | |||||||||||||||||||||||||||||
| Three Months Ended | Twelve Months Ended | ||||||||||||||||||||||||||||
| December 31, | December 31, | ||||||||||||||||||||||||||||
| (in millions) | 2023 | 2022 | 2023 | 2022 | |||||||||||||||||||||||||
| Net (loss) income attributable to Bausch + Lomb Corporation | $ | (54) | $ | (1) | $ | (260) | $ | 6 | |||||||||||||||||||||
| Interest expense, net | 96 | 44 | 268 | 140 | |||||||||||||||||||||||||
| (Benefit) provision for income taxes | (6) | (2) | 82 | 58 | |||||||||||||||||||||||||
| Depreciation and amortization of intangible assets | 116 | 93 | 382 | 379 | |||||||||||||||||||||||||
| EBITDA | 152 | 134 | 472 | 583 | |||||||||||||||||||||||||
| Adjustments: | |||||||||||||||||||||||||||||
| Asset impairments | — | — | — | 1 | |||||||||||||||||||||||||
| Restructuring, integration and transformation costs | 27 | 21 | 123 | 36 | |||||||||||||||||||||||||
| Acquisition-related costs and adjustments (excluding amortization of intangible assets) | 29 | 1 | 50 | (4) | |||||||||||||||||||||||||
| Share-based compensation | 16 | 17 | 74 | 62 | |||||||||||||||||||||||||
| Separation and Separation-related costs | 3 | 7 | 10 | 35 | |||||||||||||||||||||||||
| Other non-GAAP adjustments: | |||||||||||||||||||||||||||||
| Other | 4 | 1 | 9 | 7 | |||||||||||||||||||||||||
| Adjusted EBITDA (non-GAAP) | $ | 231 | $ | 181 | $ | 738 | $ | 720 | |||||||||||||||||||||
| Bausch + Lomb Corporation | Table 3 | |||||||||||||||||||||||||||||||||||||||||||||||||
| Constant Currency Revenue (non-GAAP) and Constant Currency Revenue Growth (non-GAAP) - by Segment | ||||||||||||||||||||||||||||||||||||||||||||||||||
| For the Three and Twelve Months Ended December 31, 2023 and 2022 | ||||||||||||||||||||||||||||||||||||||||||||||||||
| (unaudited) | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Calculation of Constant Currency Revenue for the Three Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||
| December 31, 2023 | December 31, 2022 | Change in Revenue as Reported | Change in Constant Currency Revenue (Non-GAAP) (b) | |||||||||||||||||||||||||||||||||||||||||||||||
| Revenue as Reported | Changes in Exchange Rates (a) | Constant Currency Revenue (Non-GAAP) (b) | Revenue as Reported | |||||||||||||||||||||||||||||||||||||||||||||||
| (in millions) | Amount | Pct. | Amount | Pct. | ||||||||||||||||||||||||||||||||||||||||||||||
Vision Care (c) | $ | 662 | $ | 13 | $ | 675 | $ | 624 | $ | 38 | 6 | % | $ | 51 | 8 | % | ||||||||||||||||||||||||||||||||||
| Surgical | 204 | (3) | 201 | 188 | 16 | 9 | % | 13 | 7 | % | ||||||||||||||||||||||||||||||||||||||||
Pharmaceuticals (c) | 307 | (1) | 306 | 184 | 123 | 67 | % | 122 | 66 | % | ||||||||||||||||||||||||||||||||||||||||
| Total revenues | $ | 1,173 | $ | 9 | $ | 1,182 | $ | 996 | $ | 177 | 18 | % | $ | 186 | 19 | % | ||||||||||||||||||||||||||||||||||
Calculation of Constant Currency Revenue for the Twelve Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||
| December 31, 2023 | December 31, 2022 | Change in Revenue as Reported | Change in Constant Currency Revenue (Non-GAAP) (b) | |||||||||||||||||||||||||||||||||||||||||||||||
| Revenue as Reported | Changes in Exchange Rates (a) | Constant Currency Revenue (Non-GAAP) (b) | Revenue as Reported | |||||||||||||||||||||||||||||||||||||||||||||||
| (in millions) | Amount | Pct. | Amount | Pct. | ||||||||||||||||||||||||||||||||||||||||||||||
Vision Care (c) | $ | 2,543 | $ | 61 | $ | 2,604 | $ | 2,369 | $ | 174 | 7 | % | $ | 235 | 10 | % | ||||||||||||||||||||||||||||||||||
| Surgical | 767 | 1 | 768 | 718 | 49 | 7 | % | 50 | 7 | % | ||||||||||||||||||||||||||||||||||||||||
Pharmaceuticals (c) | 836 | 6 | 842 | 681 | 155 | 23 | % | 161 | 24 | % | ||||||||||||||||||||||||||||||||||||||||
| Total revenues | $ | 4,146 | $ | 68 | $ | 4,214 | $ | 3,768 | $ | 378 | 10 | % | $ | 446 | 12 | % | ||||||||||||||||||||||||||||||||||
(a) The impact for changes in foreign currency exchange rates is determined as the difference in the current period reported revenues at their current period currency exchange rates and the current period reported revenues revalued using the monthly average currency exchange rates during the comparable prior period.
(b) To supplement the financial measures prepared in accordance with GAAP, the Company uses certain non-GAAP financial measures and ratios. For additional information about the Company’s use of such non-GAAP financial measures and ratios, refer to the “Non-GAAP Information” section in the body of the news release to which these tables are attached. Constant currency revenue (non-GAAP) for the three and twelve months ended December 31, 2023 is calculated as revenue as reported adjusted for the impact for changes in exchange rates (previously defined in this news release). Change in constant currency revenue (non-GAAP) is calculated as the difference between constant currency revenue for the current period and revenue as reported for the comparative period.
(c) Effective in the first quarter of 2023, certain products historically included in the reported results of the Pharmaceuticals segment are now included in the reported results of the Vision Care segment and certain products included in the reported results of the Vision Care segment are now included in the reported results of the Pharmaceuticals segment. Management believes these movements are necessary in order to better align these products with the groupings of similar products. The net impact of these product movements was not material to the periods presented. Prior period presentations of segment revenues have been conformed to the current segment reporting structure.